Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senicapoc in Atopic Asthma
NCT00861211Phase 2Completed
- Sponsor
- Icagen
- Start
- Oct 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of senicapoc (2 arms), sponsored by Icagen. Primary endpoint: Decrease in FEV1 between 4-10 hours (Late Asthmatic Response) after allergen challenge at 2 weeks. Started Oct 2008; status: completed.
02
Drugs
senicapoc
Beyond the preview
Go deeper on NCT00861211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861211.